JC virus infection is acquired very early in life: evidence from a longitudinal serological study.

Abstract

JC virus (JCV) is a widespread member of the Polyomaviridae family. Following primary infection, which occurs asymptomatically during childhood, JCV establishes latency in the host. JCV seroprevalence can reach 80% in healthy adults, but the age of viral exposure has not been yet characterized. This study was conducted to define JCV seroprevalence in Italian infants and to estimate the date of primary infection. A JCV viral protein 1 (VP1)-GST fusion protein was used in conjunction with a homemade indirect enzyme-linked immunosorbent assay (ELISA) to test for the presence of IgG antibodies to JCV in 981 serum samples collected from 644 Italian infants of different ages (1day to 3years old) and in 102 breast milk samples. IgM antibody presence was also evaluated in longitudinally collected samples from 17 selected children. JCV antibody prevalence and normalized optical density (nOD) were calculated. For the longitudinal analysis, generalized estimating equation techniques and spline functions were used to estimate the possible non-linear effects of time on antibody production kinetics. JCV IgG was detected in 71.8% of the sera. Prevalence increased over time from 46.1% (1month old) to 80.7% (12months old), 85.9% (24months old), and 85.5% (36months old). As determined by nOD, the longitudinal analysis of serum IgG amounts in children of this study (ages 1day to 3years old) illustrated IgG kinetic changes with statistically significant trends (p=0.001). One-month-old children were largely negative for JCV IgM (82.4%), and 58.8% of children produced JCV IgM within the second and sixth months of life. JCV IgG was detected in 27.3% of breast milk samples. JCV primary infection likely occurs before 6months of age, and a sizeable percentage of Italian infants will become JCV seropositive within 2years of age. This study can be used to determine the optimal age for potential future JCV vaccination in infants.